CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	12 Months Ended		138 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (10,915)	$ (5,629)	$ (62,317)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	9	12	546
Stock-based compensation expense	3,245	1,942	9,582
Non-cash interest expense			4,279
Change in fair value of convertible debt instrument			3,426
Change in fair value of warrant liabilities	524	1,241	(9,022)
Write off of intangible assets		15	351
Changes in operating assets and liabilities:
Grant receivable	234	(234)
Prepaid expenses and other current assets	(34)	(17)	(101)
Accounts payable and accrued expenses	1,273	(140)	2,203
Other long-term liabilities	(12)	(292)
Net cash used in operating activities	(5,676)	(3,102)	(51,053)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(5)		(426)
Change in restricted cash	(10)		(69)
Increase in patents costs and other assets			(404)
Net cash used in investing activities	(15)		(899)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of convertible debt instruments			10,621
Repayment of convertible debt instruments			(1,641)
Net proceeds from exercise of common stock warrants and options	6,067	5,206	11,293
Proceeds from shareholder advances			9
Net cash provided by financing activities	6,197	8,742	58,349
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	506	5,640	6,397
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	5,891	251
CASH AND CASH EQUIVALENTS, END OF PERIOD	6,397	5,891	6,397
SUPPLEMENTAL DISCLOSURE-Cash paid for interest			114
NONCASH FINANCING ACTIVITIES:
Issuance of equity warrants in connection with equity offerings		1,028	5,037
Conversion of accrued expenses into common stock			303
Cashless exercise of stock options	341		439
Conversion and redemptions of convertible notes and accrued interest into common stock			12,243
Conversion of extension costs related to convertible notes into common stock			171
Payment of preferred stock dividends in common stock	1,536	902	3,179
Issuance of warrants to induce conversion of notes payable			503
Issuance of stock to acquire Pro-Pharmaceuticals-NV			107
Common Stock
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of stock and warrants			28,690
Series A 12% Convertible Preferred Stock
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of stock and warrants			1,691
Series B-1 12% Redeemable Convertible Preferred Stock
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of stock and warrants			1,548
Series B-2 12% redeemable convertible preferred stock
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of stock and warrants		1,463	3,935
Series C super dividend convertible preferred stock
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of stock and warrants	$ 130	$ 2,073	$ 2,203